Apellis Pharmaceuticals Inc Market Cap ($412.48 Million)

$412.48 Million USD · Rank #12947

Market Cap & Net Worth: Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc market cap. Apellis Pharmaceuticals Inc (NASDAQ:APLS) has a market capitalization of $412.48 Million ($412.48 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12947 globally and #3202 in its home market, demonstrating a -2.22% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apellis Pharmaceuticals Inc's stock price $3.22 by its total outstanding shares 128021277 (128.02 Million). Also see APLS cash generation efficiency for how efficiently the company converts equity into cash flow.

Apellis Pharmaceuticals Inc Market Cap History (2017–2026)

Apellis Pharmaceuticals Inc market cap history from 2017 to 2026. Data shows change from $2.78 Billion to $412.48 Million (-15.36% CAGR). Check latest Apellis Pharmaceuticals Inc stock price today for real-time trading data and today's change.

Index Memberships

Apellis Pharmaceuticals Inc is a constituent of 3 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
NASDAQ Health Care IXHC	$2.62 Trillion	0.02%	#353 of 976
NASDAQ Composite IXIC	$40.12 Trillion	0.00%	#1282 of 3165
NASDAQ Biotechnology NBI	$1.84 Trillion	0.02%	#194 of 263

Weight: Apellis Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Apellis Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Apellis Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Apellis Pharmaceuticals Inc (APLS) net asset momentum to track how rapidly the company is growing its equity base year over year.

Latest Price to Sales (P/S) Ratio

3.20x

Apellis Pharmaceuticals Inc's market cap is 3.20 times its annual revenue

Industry average: 4569.38x Lower than industry average

Latest Price to Earnings (P/E) Ratio

143.64x

Apellis Pharmaceuticals Inc's market cap is 143.64 times its annual earnings

Industry average: 1.44x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2020	$7.32 Billion	$250.65 Million	-$344.87 Million	29.22x	N/A
2021	$6.05 Billion	$66.56 Million	-$746.35 Million	90.93x	N/A
2022	$6.62 Billion	$75.42 Million	-$652.17 Million	87.77x	N/A
2023	$7.66 Billion	$396.59 Million	-$528.63 Million	19.32x	N/A
2024	$4.09 Billion	$781.37 Million	-$197.88 Million	5.23x	N/A
2025	$3.22 Billion	$1.00 Billion	$22.39 Million	3.20x	143.64x

Competitor Companies of APLS by Market Capitalization

Companies near Apellis Pharmaceuticals Inc in the global market cap rankings as of November 5, 2026. Also see Apellis Pharmaceuticals Inc asset portfolio for a full breakdown of the balance sheet.

Key companies related to Apellis Pharmaceuticals Inc by market ranking:

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#181	Vertex Pharmaceuticals Inc	NASDAQ:VRTX	$130.90 Billion	$549.04
#373	Regeneron Pharmaceuticals Inc	NASDAQ:REGN	$76.14 Billion	$930.67
#415	CSL Ltd	AU:CSL	$67.74 Billion	AU$197.34
#503	Moderna Inc	NASDAQ:MRNA	$54.14 Billion	$258.38

Market Capitalization of Apellis Pharmaceuticals Inc (2017–2026)

Market capitalization of Apellis Pharmaceuticals Inc from 2017 to today. Between 2017 and today, Apellis Pharmaceuticals Inc's market cap moved from $2.78 Billion to $ 412.48 Million, with a yearly change of -15.36%.

Year	Market Cap	Change (%)
2026	$412.48 Million	-87.17%
2025	$3.22 Billion	-21.28%
2024	$4.09 Billion	-46.69%
2023	$7.66 Billion	+15.76%
2022	$6.62 Billion	+9.37%
2021	$6.05 Billion	-17.34%
2020	$7.32 Billion	+86.81%
2019	$3.92 Billion	+132.15%
2018	$1.69 Billion	-39.22%
2017	$2.78 Billion	--

End of Day Market Cap According to Different Sources

On Nov 5th, 2026 the market cap of Apellis Pharmaceuticals Inc was reported to be:

Source	Market Cap
Yahoo Finance	$412.48 Million USD
MoneyControl	$412.48 Million USD
MarketWatch	$412.48 Million USD
marketcap.company	$412.48 Million USD
Reuters	$412.48 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Apellis Pharmaceuticals Inc

NASDAQ:APLS USA Biotechnology

Market Cap

$412.48 Million

Market Cap Rank

#12947 Global

#3202 in USA

Share Price

$3.22

Change (1 day)

+3.29%

52-Week Range

$3.05 - $41.12

All Time High

$93.31